Amotosalen‐HCl‐UVA pathogen reduction does not alter poststorage metabolism of soluble CD40 ligand, Ox40 ligand and interkeukin‐27, the cytokines that generally associate with serious adverse events

Platelets in therapeutic platelet concentrates are commonly acknowledged to release biologically active constituents during storage. This study examined the influence of photochemical pathogen reduction treatment (PRT) using amotosalen‐HCl and UVA light vs. untreated control platelet components, on three factors recently reported to be associated with serious adverse events associated with platelet component (PC) transfusions: sCD40L, IL‐27 and sOX40 ligand. Levels of such cytokine‐like factors increased significantly during storage, but no significant difference was detected between PRT‐ and control PCs. This suggests that occurrences of AEs are not directly influenced by PRT but rather may depend on alternate determinants.

[1]  B. Pozzetto,et al.  Immune‐reactive soluble OX40 ligand, soluble CD40 ligand, and interleukin‐27 are simultaneously oversecreted in platelet components associated with acute transfusion reactions , 2014, Transfusion.

[2]  M. Muench,et al.  Immune modulation and lack of alloimmunization following transfusion with pathogen‐reduced platelets in mice , 2013, Transfusion.

[3]  Nancy M. Heddle,et al.  Clinical trials evaluating pathogen‐reduced platelet products: methodologic issues and recommendations , 2013, Transfusion.

[4]  J. Cazenave,et al.  Preserved functional and biochemical characteristics of platelet components prepared with amotosalen and ultraviolet A for pathogen inactivation , 2013, Transfusion.

[5]  C. Silliman,et al.  Biological response modifiers in photochemically pathogen‐reduced versus untreated apheresis platelet concentrates , 2013, Transfusion.

[6]  M. Muench,et al.  Prevention of Alloimmunization and Induction of Partial Tolerance Following Transfusion with Pathogen Reduced Platelets in Mice , 2011 .

[7]  T. Hervig,et al.  Current debate on pathogen inactivation of platelet concentrates--to use or not to use? , 2010, Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis.

[8]  T. Hervig,et al.  A prospective observational cohort safety study of 5106 platelet transfusions with components prepared with photochemical pathogen inactivation treatment , 2008, Transfusion.

[9]  O. Garraud,et al.  Release of immune modulation factors from platelet concentrates during storage after photochemical pathogen inactivation treatment , 2008, Transfusion.

[10]  B. Molini,et al.  Photochemical treatment of platelet concentrates with amotosalen and long‐wavelength ultraviolet light inactivates a broad spectrum of pathogenic bacteria , 2004, Transfusion.

[11]  Laurence Klotz.  Reactions , 2002, The Lancet.

[12]  J. Hearst,et al.  Photochemical inactivation of viruses and bacteria in platelet concentrates by use of a novel psoralen and long‐wavelength ultraviolet light , 1997, Transfusion.